Hyeon-Ok Jin1, Sung-Eun Hong2, Ji-Young Kim3, Se-Kyeong Jang2, Young-Sun Kim3, Ju-Hee Sim3, Ac-Chin Oh4, Heyjin Kim4, Young Jun Hong4, Jin-Kyung Lee3,4, In-Chul Park5. 1. KIRAMS Radiation Biobank, Korea Institute of Radiological and Medical Sciences, Seoul, Republic of Korea hyeonok@kirams.re.kr parkic@kirams.re.kr. 2. Division of Fusion Radiology Research, Korea Institute of Radiological and Medical Sciences, Seoul, Republic of Korea. 3. KIRAMS Radiation Biobank, Korea Institute of Radiological and Medical Sciences, Seoul, Republic of Korea. 4. Department of Laboratory Medicine, Korea Institute of Radiological and Medical Sciences, Seoul, Republic of Korea. 5. Division of Fusion Radiology Research, Korea Institute of Radiological and Medical Sciences, Seoul, Republic of Korea hyeonok@kirams.re.kr parkic@kirams.re.kr.
Abstract
BACKGROUND/AIM: Phosphoserine aminotransferase 1 (PSAT1) is an enzyme implicated in serine biosynthesis, and its overexpression has been linked to cancer cell proliferation. Therefore, targeting PSAT1 is considered to be an anticancer strategy. MATERIALS AND METHODS: The viability of non-small cell lung cancer (NSCLC) cells was measured by MTT assay. Protein and mRNA expression were determined by western blot and reverse transcription polymerase chain reaction, respectively. RESULTS: Glutamine-limiting conditions were generated through glutamine deprivation or CB-839 treatment, which induced PSAT1 expression in NSCLC cells. PSAT1 expression induced by glutamine-limiting conditions was regulated by activating transcription factor 4. Knock-down of PSAT1 enhanced the sensitivity of NSCLC cells to glutamine-limiting conditions. Interestingly, ionizing radiation induced PSAT1 expression, and knocking down PSAT1 increased cell sensitivity to ionizing radiation. CONCLUSION: Inhibiting PSAT1 might aid in the treatment of lung cancer, and PSAT1 may be a therapeutic target for lung cancer. Copyright
BACKGROUND/AIM: Phosphoserine aminotransferase 1 (PSAT1) is an enzyme implicated in serine biosynthesis, and its overexpression has been linked to cancer cell proliferation. Therefore, targeting PSAT1 is considered to be an anticancer strategy. MATERIALS AND METHODS: The viability of non-small cell lung cancer (NSCLC) cells was measured by MTT assay. Protein and mRNA expression were determined by western blot and reverse transcription polymerase chain reaction, respectively. RESULTS:Glutamine-limiting conditions were generated through glutamine deprivation or CB-839 treatment, which induced PSAT1 expression in NSCLC cells. PSAT1 expression induced by glutamine-limiting conditions was regulated by activating transcription factor 4. Knock-down of PSAT1 enhanced the sensitivity of NSCLC cells to glutamine-limiting conditions. Interestingly, ionizing radiation induced PSAT1 expression, and knocking down PSAT1 increased cell sensitivity to ionizing radiation. CONCLUSION: Inhibiting PSAT1 might aid in the treatment of lung cancer, and PSAT1 may be a therapeutic target for lung cancer. Copyright
Authors: Jiancai Wang; Xiang Sun; Jiayuan Wang; Kun Zhang; Yiyi Yuan; Yan Guo; Libo Yao; Xia Li; Lan Shen Journal: Am J Cancer Res Date: 2022-08-15 Impact factor: 5.942